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Sunmnary A reliable test that detects malignancy and indicates response to therapy is needed. Frequency-
pulsed electron-capture gas-liquid chromatography (FPEC-GLC), a selective analytical technique that is
sensitive to 15 fmol quantities of metabolites, was used to analyse derivatised acidic chloroform extracts of
sera from patients with biopsy-proven cancer, non-malignant infectious and non-infectious disease, and
healthy controls. Two peaks designated PI and Pl0, not found in serum from healthy controls (n = 7) or
patients with non-malignant disease (n = 85), were detected in biopsy-proven samples (n = 52) from cancer
patients. PI and Pl0 were later shown by chemical and mass spectral studies to be carboxylic acids. When one
or both of these peaks were detected in the sera of non-treated patients they were always associated with
malignancy. In patients responding to therapy, a reduction or disappearance of these peaks was observed.
Further, it was noted that P10 persisted or increased in sera of patients with progressive cancer not responding
to therapy. We conclude that this test has potential in diagnosis and for following the response of the disease
to therapy.
Approximately 25% of all deaths in the USA are the result
of cancer (Sondik, 1988). Because this may be due in part to
the lack of early detection and treatment, attempts have been
made to develop tests useful for the early diagnosis of cancer.
These include the detection of carcinoembryonic antigen,
alpha-fetoprotein and tumour-associated antigens and
nuclear magnetic resonance. Unfortunately, these tests have
unacceptably low sensitivity and specificity for the diagnosis
of cancer, and their primary use is as markers of disease
activity (Garrett & Kurtgis, 1985; Engan et al., 1990; Sell,
1990).
Frequency-pulsed electron-capture gas-liquid chromato-
graphy (FPEC-GLC) of various body fluids has been used to
detect metabolites associated with infectious and non-
infectious diseases (Brooks et al., 1972, 1986, 1987, 1990;
Daneshavar et al., 1988). In these studies, diagnostic FPEC-
GLC profiles were characterised by comparing specimens
from patients with disease and healthy controls. During our
studies of cerebrospinal fluid (CSF) and serum from patients
with suspected tuberculous meningitis, we received several
specimens from persons who were later determined to have
cancer, identified infection or characterised non-infectious
disease. After observing several reproducible FPEC-GLC
profiles from specimens of patients who had a final diagnosis
of cancer and then enhancing the peaks of certain
metabolites repeatedly associated with the disease, we began
prospectively testing sera ofpatients with cancer to determine
the ability of FPEC-GLC to detect cancer-associated
metabolites.
Methods
Patient selection
Serum samples from 52 patients with biopsy-proven malig-
nant tumours were collected from patients in Norfolk and
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Hampton, Virginia, and Halifax, Nova Scotia. The histo-
logical type of tumour was determined by microscopic
examination of biopsied tissue by pathologists at the par-
ticipating institutions. Specimens were obtained from patients
before, during or after therapy (surgery, radiation or
chemotherapy). The impact of therapy was reported by the
patient's physician as effective, partially effective or
ineffective; no uniform objective criteria were applied for this
classification. FPEC-GLC profiles also were determined for
serum and CSF specimens of 94 controls who either were
healthy or had a variety of non-neoplastic conditions. The
latter specimens were originally sent for evaluation of possi-
ble tuberculous meningitis.
Collection ofblood
Blood (1Oml) was collected from patients, and allowed to
clot and retract at room temperature. Serum was separated
from the clot by centrifugation at 2,000 g for 5 min and then
transferred with sterile Pasteur pipettes to a 15 ml conical
screw-capped centrifuge tube (Corning Glass Company, NY,
USA). The sample was centrifuged again at 2,000g for 5 min
to remove residual red blood cells. The serum supernatant
was transferred to sterile tubes for storage at - 70°C without
any chemical additives or preservatives. All samples were
shipped to the Centers for Disease Control Laboratory on
dry ice to prevent thawing before analysis.
Frequency-pulsed electron-capture gas-liquid chromatography
Trichloroethanol (TCE) esters were prepared by the method
described by Brooks et al. (1990) using an internal standard
(C) and C18 reversed-phase column clean-up. The sample
was placed in 200 y1 of a final solvent of 50% (v/v) xylene-
ethanol, and the sample was transferred to a Teflon-lined
screw-cap glass inserted vial (National Scientific, Lawrence-
ville, GA, USA) and 2 1l was injected by autosampler. The
samples were analysed by FPEC-GLC as previously de-
scribed (Brooks et al., 1990). Specimens included in this
study were coded, and the FPEC-GLC chromatograms were
grouped blinded to diagnosis (Table I).
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Mass spectral analysis
For mass spectral (MS) analysis of cancer-associated
metabolites, pentafluorobenzylbromide (PFB) derivatives
were prepared from acidic chloroform extracts (Daneshvar &
Brooks, 1988) of sera from cancer patients shown by
previous FPEC-GLC analysis to contain large quantities of
these metabolites. The first MS study used a Finnigan TSQ
46 gas chromatography-mass spectrometry data system
equipped with a splitless injector and an OV-1 fused-silica,
large-bore, bonded-phase capillary column, as described
above for FPEC-GLC analysis. The carrier gas was helium at
a flow rate of 1 ml min-'. The derivatised sample (4ttl) was
injected into the instrument and kept at 90°C for 3 min. The
injector was then maintained at 180°C, vented and the in-
strument was programmed for a linear temperature increase
of 6°C min-' to 275°C and was kept isothermal at this
temperature for 26 min. Electron impact spectra and positive
and negative chemical ionisation spectra were obtained. The
reagent gas used for CI was methane (Matheson, Suwanee,
GA, USA).
For the second MS study, we used gas chromatography
(GC)-MS and MS-MS. Spectra were acquired using a
Finnigan TSQ-70 instrument equipped with a Hewlett-
Packard 5880 GC (Atlanta, GA, USA). The 5880 GC was
equipped with a 30 m x 0.25 mm ID fused-silica column
coated with a 0.25 ytm film of DB-1 (J & W Scientific,
Folsom, CA, USA). For analysis, the injector and transfer
temperatures were maintained at 300°C while the column
temperature was held isothermal at 90°C for 4 min, then
programmed for a linear increase of 4°C min-' to 275°C and
held at this temperature for 30 min. The column was coupled
directly into the electron or chemical ionisation source, which
was maintained at 160°C. Spectra were recorded over a range
of 50-700 a.m.u. s- using the Finnigan ICIS data system
(Houston, TX, USA). Daughter spectra were obtained by
mass selecting the appropriate ion in the first quadrupole,
dissociating it up on collision with millitorr argon at energies
of 20-30 eV in the second quadruple, and scanning the third
quadrupole. Background spectra were subtracted from the
spectra of interest.
Statistical methods
Associations between FPEC-GLC peaks 1 and 10 and type
or site of tumour or treatment efficacy were determined in
2 x 2 tables using the chi-square test; when one or more cells
had an expected value of less than 5, the two-tailed Fisher
exact test was used. The association between increasing
effectiveness of therapy and the presence of these peaks was
determined using the chi-square test for linear trend. The
height of Plo was associated with treatment effectiveness
using the Kruskal-Wallis test for non-normally distributed
data.
Results
A total of 52 patients with malignancy were studied. Primary
tumour sites and histological types are shown in Table I. The
most common primary sites were breast (22), colon (11) and
lung (9). The most common histological type was adenocar-
cinoma (30). Patients ranged in age from 2 to 75 years (mean
55). Ten patients had received no treatment; for those who
had received therapy, treatment was classified as ineffective
for 10, partially effective for 17 and effective for 14 (Table I).
A total of 94 patients were studied, which included healthy
subjects, patients characterised as having non-malignant
diseases and patients with various characterised infectious
diseases. The patients with infectious diseases were also
examined as controls.
Identification ofcancer-associated metabolites
Four FPEC-GLC patterns were observed among the 52 spec-
imens from cancer patients (Table I and Figures 1-4). These
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patterns were grouped as follows:
1. Group 1: Specimens contained a peak designated P1
alone or in combination with a peak designated as Plo
shown in Figure la and b, Figure 2a and b and Figure
3a.
2. Group 2: Specimens contained Plo along with additional
peaks not found in controls, but found in advanced
cancer cases (Figure 4a).
3. Group 3: Specimens contained Plo and peaks associated
with controls (Figure 4b).
4. Group 4: Specimens that had an FPEC-GLC profile
that was like healthy controls without P1 and Plo
(Figure lc and Figure 2c).
P1 was detected on an OV-1 column (Figure 1, chromato-
gram A). This peak was enhanced by extraction using a C18
RPC column as seen by comparing computer-expanded por-
tions of FPEC-GLC patterns (Figure la and b). P1 was not
found in the enhanced specimen from healthy controls
(Figure lc). It possessed unusual chromatographic charac-
teristics in that the TCE ester did not elute on polar OV-225
or on the moderately polar OV-1701 capillary columns, and
the ester slowly decomposed after standing for a month at
4°C. P1 was extractable with chloroform under acidic but not
basic conditions. It did not react with heptafluorobutyric
anhydride either before or after esterification with TCE or
PFB, and the TCE ester did not react with hydrogen in the
presence of a platinum catalyst; therefore, PI was determined
to be a saturated, short-chain, carboxylic acid without free
amine or hydroxyl groups.
MS analysis of TCE-derivatised samples that contained
large amounts (five times full scale) of P1 by FPEC-GLC
analysis was attempted on two occasions without obtaining
meaningful spectra. We next used MS to analyse PFB-
derivatised acidic chloroform extracts of sera taken from the
same patients as the sera initially tested as TCE derivatives,
and we were able to obtain mass spectra on PI. The positive
methane chemical ionisation mass spectrum of P1 (Figure Sa)
showed the protonated molecule at m/z 271 and fragments at
m/z 243, 225 and 181 (base peak). The m/z 181 fragment is
also the base peak in the electron ionisation mass spectrum
of PI, which includes a subsequent hydrogen fluoride (HF)
loss fragnent at m/z 161 but no molecular ion. The mole-
cular weight is confirmed from its negative methane chemical
ionisation mass spectrum whose base peak was the m/z 89
fragment formed from dissociative electron attachment, re-
sulting in the loss of the PFB derivative. Mass selection of
the m/z 89 anion with subsequent collisional activation and
daughter ion analysis indicated two fragments at m/z 43 and
45. From the spectra we concluded that P1 was a monocar-
boxylic acid and that the underivatised acid had a molecular
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Figure 1 Frequency-pulsed electron-capture gas-liquid
chromatography (FPEC-GLC) chromatograms of trichloro-
ethanol (TCE) derivatives prepared from acidic cholorform ex-
tracts of serum taken from a patient with transitional cell car-
cinoma of the bladder. Chromatogram a shows peak (PI)
before the sample was processed through the reversed-phase
chromatography (RPC) column. Chromatogram b shows P1 after
RPC column clean-up, and chromatogram c is the control serum
that, like b, also received RPC column clean-up. Only a segment
of the chromatogram from 0 to 40 min is shown. The subscript
number after the letter C indicates the number of carbon atoms,
and the number after the colon is the number of unsaturated
bonds. The letter i indicates a methyl group at the iso position in
the carbon chain. Heptanoic acid (C7) is the internal standard
(IS) added to the serum sample prior to extraction and deriva-
tion.
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Figure 2 FPEC-GLC chromatograms of TCE derivatives pre-
pared from acidic chloroform extracts of sera taken from two
patients with early adenocarcinoma of the colon (chromatograms
a and b; Table I, samples 7 and 8) and a suspected case of colon
cancer that was later determined to be pancreatitis and had
recovered to give an FPEC-GLC profile like a healthy control
(chromatogram c). See legend to Figure I for definition of ab-
breviations. PAA, phenylacetic acid.
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weight of 90. The following acids, which were considered as
likely candidates for P1, either did not co-elute with P1 on the
OV-1 column or failed to derivatise with TCE: methoxyacetic
(the most likely candidate based on fragmentation studies),
0~~~~~~~
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Time (min)
Figure 3 FPEC-GLC chromatograms of TCE derivatives pre-
pared from acidic chloroform extracts of sera. Chromatogram a
was obtained by FPEC-GLC analysis of serum taken from a
patient with early untreated squamous cell carcinoma of the nose,
and chromatogram b was obtained by FPEC-GLC analysis of
serum taken from the same patient shown in chromatogram a
months after surgical removal of the cancer (Table I, samples I
and 2). See legend to Figure I for definition of abbreviations.
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lactic, 3-hydroxypropionic and oxalic acids. Other com-
pounds such as 1-ketobutyric, acetoacetic, ethyl-3-ethoxy-
acrylic and 2-methylbutyric acids succinicsemialdehyde were
analysed by FPEC-GLC, but none of these co-eluted with P,.
XL
0
12 22 32 42 52 62 72
122°C 4CCmin-'___ 275SC
Time (min)
Figure 4 FPEC-GLC chromatograms of TCE derivatives pre-
pared from acidic chloroform extracts of sera taken from a
patient with adenocarcinoma of the sigmoid colon (chromato-
gram a). Therapy for 0.17 years (about 9 weeks) was ineffective
and metastasis occurred. Chromatogram b (Table I, sample 37)
was obtained by FPEC-GLC analysis of serum from a patient
with progressive adenocarcinoma of the colon. See legend to
Figure I for definition of abbreviations.
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Figure 5 Positive chemical ionisation gas-liquid chromatography mass spectra of P, (a) and Pl0 (b). The PFB derivatives were
prepared from acidic chloroform extracts of serum taken from a patient with advanced cancer.
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We were also able to obtain electron impact and positive
and negative chemical ionisation spectra on Plo. The positive
methane chemical ionisation mass spectrum (Figure 5b)
100
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mlz
Figure 6 Electron impact spectra obtained from the mass spect-
ral analysis of the trichloroethyl ester of Plo.
showed the protonated molecule at m/z 601 with loss of
pentafluorobenzylalcohol at m/z 403 and the m/z 181 frag-
ment discussed previously. A weak fragment at m/z 239 was
evident, indicating the possible loss of two PFB molecules.
The negative methane chemical ionisation spectrum showed
the analogous m/z 419 fragment, corresponding to the loss of
the PFB derivative. Loss of carbon dioxide from the m/z 419
ion yielded the m/z 375 ion, and loss of a second PFB was
noted at m/z 239. Subsequent loss ofcarbon dioxide from the
apparent second dicarboxylic fragment at m/z 239 yielded the
m/z 195 fragment. The electron ionisation mass spectrum
gave a strong molecular ion at m/z 600 with the loss of PFB
at m/z 419, and the PFB fragment was the base peak at m/z
181. A weak m/z 238 was noted as well as the loss of carbon
dioxide from m/z 419 to give the m/z 375 fragment. These
data strongly indicated a molecular weight of 600 for the
PFB derivative of peak 10.
Similarly, analysis of the TCE derivative of Plo using elec-
tron ionisation gave the bis-TCE derivative at m/z 500. The
isotopic distribution was that expected for the hexachloro
derivative formed by attachment of two TCE reagents to Plo.
Loss of trichloroethanol gave the m/z 353 fragment with a
significantly less complex isotopic distribution. Loss of 29
a.m.u. from m/z 500 and m/z 353 is apparently responsible
for the m/z 471 fragment and the m/z 324 fragment. The
negative methane chemical ionisation mass spectrum of Plo
confirmed both the electron impact spectrum of the bis-TCE
derivative and that of the bis-PFB derivative data given in
the preceding paragraph. The base peak of the negative
chemical ionisation spectra at m/z 369 showed an isotopic
distribution containing three chlorines. A weak molecular
ion, which contained the characteristic six-chlorine isotopic
distribution, was seen at m/z 500. The molecular weight of the
bis-PFB derivative is 600, while that of the bis-TCE
0 a
MW= 500 1°l Hs CH2-CH2-CH2C =C-O-C-0-CH3-CCI3
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Figure 7 Proposed fragments obtained from mass spectral analysis of the trichloroethyl ester of PlO.FPEC-GLC DETECTION OF MALIGNANCY 661
derivative is 500. Together, these data indicate a molecular
weight of 240 for the underivatised Pl0. The derivatised com-
pound contains two TCE groups or two PFB groups,
indicating that it is a dicarboxylic acid. The fragmentation
pattern of the electron impact spectra (Figure 6) indicates a
highly oxygenated compound with a very tentative structure
presented (Figure 7). Evidence has been presented
(McDonagh et al., 1992) that monocytes and macrophages,
in response to malignant tumours, release components that
affect lipid metabolism and perioxidation was presented as
one mechanism. Pl0, like Pi, was not detected on the OV-225
polar column. In addition to peaks 1 and 10, several other
peaks not found in controls were found in specimens from
some cancer patients (Figure 4, peaks 3, 4, 7, 8 and 9). These
substances were not always found in specimens that contain
Plo and they were usually seen in patients seriously ill with
cancer. They have not been characterised further.
Relationship ofcancer-associated metabolites and clinical
findings
Of the specimens from 52 patients with malignancy, P1 was
identified in FPEC-GLC profiles of 17 (33%), Pl0 in profiles
of 37 (73%), and either peak in 42 (82%). When the entire
profile was analysed, abnormalities were noted in 48 (94%)
of the 52. Of the abnormal 92 control patients profiles, none
contained Pi, Pl0 or peaks associated with the cancer groups
(Figure 4a). Thus, in our series, the sensitivity of FPEC-GLC
for malignancy was 82% when considering only P1 and Pl0,
or 94% when considering other abnormalities that occurred
in the cancer groups, and the specificity was 100%. The
quantity of P1 or Pl0 decreased with increasing effectiveness
of therapy: sensitivity was 100% in profiles of patients who
had received no therapy or ineffective therapy, 88% in those
of patients whose therapy was partially effective and 50% in
those of patients who had received effective therapy
(P<0.001, chi-square for linear trend). No significant
differences were seen in the proportion of samples containing
these peaks by tumour site or type when the analysis was
stratified for the effect of therapy.
Treatment had a significant effect on the presence of both
P1 and Plo. P1 was present in profiles of 9 (90%) of 10
patients who had not received therapy compared with 8
(20%) of 41 patients who had received any therapy
(P<0.001), regardless of its efficacy. In contrast, Pl0 was
present in most FPEC-GLC profiles of all treatment groups
except for those with therapy classified as effective [34 (92%)
of 37 patients with no treatment or ineffective or partially
effective therapy versus 3 (21%) of 14 patients with effective
therapy, P = 0.001]. The height of Plo was also significantly
less in the profiles of those who had received effective therapy
compared with the other patient groups (4% full scale com-
pared with 36% full scale, P<0.001). The effect of treatment
on the FPEC-GLC profile was consistent regardless of
tumour site and type.
Discussion
The use of serum markers for the diagnosis and prognosis of
cancer has been reviewed (Bates & Lono, 1987). Some of the
markers extensively investigated for their value include car-
cinoembryonic antigen, alpha-fetoprotein, human chorionic
gonadotrophic hormone and prostatic acid phosphatase.
These markers most often are measured by radioimmunoas-
says (RIAs). While the assays detect nanogram levels of the
markers, they lack the sensitivity and specificity to serve as
screening tools for the early detection of cancer and have
been most effective in disease management or for following
the progression of previously diagnosed cancer.
More recently, the analysis of human plasma by nuclear
magnetic resonance (NMR) was used to discriminate between
healthy controls and cancer patients (Fossel et al., 1986).
However, further studies have indicated that this method
lacks the specificity to serve as a test for the early diagnosis
of cancer (Okunieff et al., 1990; Shulman, 1990).
In the current study, detection of two peaks (P1 and Pl0) by
FPEC-GLC of serum specimens was a sensitive and specific
test for identifying patients with a variety of malignancies.
Since FPEC-GLC can detect femtomole quantities of
derivatised electron-absorbing compounds, it may be more
sensitive than either RIA or NMR. Additionally, FPEC-
GLC is specific for electron-absorbing compounds. Instru-
mentation for FPEC-GLC can be automated and is much
less expensive than equipment needed for NMR analysis.
Results from selected chemical tests and mass spectroscopy
suggest that P1 is a monocarboxylic and Plo a dicarboxylic
acid and that both are highly oxygenated. While these results
reflect progress in their characterisation, the true structural
formula of these components remains to be developed. An
accurate knowledge of their structure will be valuable in
identifying the metabolic origin of these substances in
patients with cancer.
Accurate mass measurements of the various ionic forms of
P1 and Plo should be undertaken to establish their molecular
formulae and to better define their fragmentation. Infrared
spectroscopy in combination with gas chromatography may
also provide some additional information regarding the
nature of these compounds. Finally, MS in combination with
liquid chromatography may be necessary to isolate sufficient
quantitites of purified P1 and Plo for NMR analyses.
Peaks 1 and 10 cannot be absolutely quantitated on a
molar basis by FLPEC-GLC without positive identification
and comparison of the detector response to the actual com-
pound because the response of the detector depends on the
electron-absorbing characteristics of the derivatised com-
pound; however, observations on peak concentration made
from peak height and area obtained by comparison with an
internal standard are valid. Although our study suggests that
detection of specific peaks in specimens examined by FPEC-
GLC was both sensitive and specific for patients with malig-
nancy, the principal value of this procedure depends on its
ability to detect malignancies early (before clinical signs or
other diagnostic tests) or its ability to be used as a marker
for the efficacy of therapy. Some data suggest that the
presence and concentration of these metabolites vary with the
success of therapy; however, the effect of therapy was not
well quantified and serial specimens obtained during therapy
from individual patients were not available. Prospective
longitudinal studies of patients undergoing therapy are
needed in order to validate this test's utility in monitoring the
impact of treatment. Determining whether this procedure is
useful as a diagnostic test might be accomplished by testing
patients in groups at high risk for developing a malignancy
and prospectively following patients with positive and
negative test results for the development of cancer detected
by standard methods.
FPEC-GLC tests on clinical samples of body fluids for
tuberculous meningitis have been reported (Brooks et al.,
1990), and are presently being conducted by this laboratory.
Further, the derivatisation technique used in the study has
been refined and made practical, highly reproducible and
reliable. Samples can be automatically injected into the gas
chromatograph, and computers are available that expedite
the handling of the data.
Results from this study indicate that FPEC-GLC may
eventually offer the physician a means to screen and diagnose
malignancies and to determine the effectiveness of cancer
therapy.
The authors thank Dr C.W. Moss for his support of the
project.662 J.B. BROOKS et al.
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